Boditech Highlights Automated Benchtop and Handheld Immunoassay Readers at MEDICA 2022
|
By LabMedica International staff writers Posted on 15 Nov 2022 |
|
Image: AFIAS MxA/CRP is the world’s first automated immuno-fluorescence quantitative assay (Photo courtesy of Boditech)
Boditech Med (Gang-won-do, Korea) is presenting its portfolio of latest IVD solutions, including TDM, AMS, and TB diagnostic tests, at this year's MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany.
At MEDICA 2022, Boditech is showcasing the AFIAS-1 immunoassay analyzer with an all-in-one cartridge system. The AFIAS-1 is a compact, single channel lateral flow immunoassay platform with a disposable cartridge that includes all the reagents necessary for the test. Also on display is the Boditech Quick COVID-19 Ag Nasal quick and simplified rapid test kit that determine COVID-19 antigen with a nasopharyngeal or nasal swab. Boditech Quick COVID-19 Ag Nasal can help to quickly and accurately determine the presence or absence of SARS-CoV-2 antigen at anytime and anywhere. It is very useful as a screening test for SARS-CoV-2 virus infection (COVID-19).
Among its other diagnostic tests, Boditech is highlighting the Alpha-Fetoprotein (AFP) test for diagnosing cancers (liver, testicles and ovaries) & monitoring the therapeutic effect. High levels of AFP in adults may indicate the possibility of the liver, the ovaries, or the testicles, as well as noncancerous liver diseases such as cirrhosis and hepatitis. The AFP plus measures the level of AFP to help diagnose or rule out related abnormalities. Visitors to Boditech’s booth at MEDICA 2022 can also get insights into the company’s AFIAS MxA/CRP combo test that assists in diagnosing viral & bacterial infections by measuring virus-specific markers and CRP simultaneously. The AFIAS MxA/CRP combo test is available on the company’s AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10 instruments to support the diagnosis of viral and/or bacterial infection. Boditech has also announced that it will be officially launching its new ichroma Cyfra21-1 which is a tumor marker of NSCLC (non-small cell lung cancer) in early December.
Related Links:
Boditech Med
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Pipette Calibration System
Artel PCS®
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Latest MEDICA 2022 News
- Bosch Demonstrates Vivalytic All-In-One PCR Analyzer at MEDICA 2022
- Biovendor Group Presents CLIA Solution for Complex Diagnostics at MEDICA 2022
- Diatron Exhibits Advanced Hematology and Clinical Chemistry Analyzers at MEDICA 2022
- Immundiagnostik AG Presents New PCR Test MutaPLEX RespiraScreen4_Diff_seqc at MEDICA 2022
- Eurotrol Presents the Future of Blood Gas Controls at MEDICA 2022
- Rhinomed Announces European Launch of Revolutionary New Swab for Testing Children for Respiratory Diseases
- Absology Exhibits POCT Immunoassay Analyzer with Testing Time of Five Minutes
- Cormay Diagnostics Introduces True 5+ DIFF Multi-Patented Hematology Solution at MEDICA 2022
- EDAN Takes its Solutions up a Notch at MEDICA 2022
- Bioneer Presents Near-Patient POC Molecular Diagnostic System at MEDICA 2022
- Rhinostics Features New RHINObot Automated Decapper at MEDICA 2022
- MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022
- Oxford Immunotec Showcases Automated T-SPOT.TB Test at MEDICA 2022
- Co-Diagnostics Introduces its CoPrimer Technology and Applications at MEDICA 2022
- Sentinel Diagnostics Presents New Fully Automated Sample to Result System for Diagnosis of Viral Infections
- Serosep Exhibits EntericBio System for Testing, Detecting and Identifying GI Pathogens at MEDICA 2022
Channels
Clinical Chemistry
view channel
Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more
Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
Diagnosing malignancy from pleural effusion remains challenging because tumor cells are rare and clusters are easily disrupted during processing. Conventional cytology can miss malignant tumor cells and... Read more
Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read moreMolecular Diagnostics
view channel
AI Blood Test Enhances Monitoring of Liver Cirrhosis Progression
Monitoring chronic liver disease remains difficult because clinicians rely on tools that can be inconsistent and may miss early progression. Standard approaches often combine ultrasound imaging with blood-based... Read more
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read moreHematology
view channel
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Immunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more
Microbiology
view channel
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria
Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
Microscopy images contain rich clues about cell health, but many disease-relevant morphological differences are too subtle to see and difficult to quantify consistently. Artificial intelligence (AI) has... Read more
Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
Many patients with advanced melanoma start on anti-PD-1 immunotherapy, but responses can wane or never develop. Clinicians often turn to anti-CTLA-4 after resistance emerges, yet predicting who will respond... Read more
Technology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more
Industry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more